The accumulation of hyperphosphorylated tau protein into neurofibrillary tangles is a central pathological feature of Alzheimer’s disease and other tauopathies. Molecular chaperones, particularly Heat Shock Protein 70 (Hsp70), play a pivotal role in maintaining proteostasis by facilitating the proper folding, refolding, or degradation of misfolded proteins. Among its isoforms, Hsc70 (HSPA8) and Hsp72 (HSPA1A) are key regulators of tau turnover, with Hsp72 being more closely linked to the promotion of tau degradation via the ubiquitin-proteasome system. Pharmacological modulation of Hsp70 activity offers a promising strategy for reducing pathogenic tau levels. Allosteric inhibitors that stabilize a conformation of Hsp70 favoring substrate degradation have demonstrated efficacy in preclinical models.
In this study, we report the development of a new series of Hsp70 allosteric inhibitors derived from the rhodacyanine scaffold, focusing on enhancing metabolic stability while preserving biological activity. The lead compound, YM-08, exhibited favorable brain penetration and reduced tau levels but was rapidly metabolized in liver microsomes, with a half-life under three minutes. Metabolite identification studies revealed that the benzothiazole ring served as the primary site for CYP3A4-mediated oxidation. To address this issue, we introduced halogen substitutions—fluorine and chlorine—at various positions (3-, 4-, 5-, and 6-) on the benzothiazole ring. We also explored the impact of shifting the pyridine nitrogen from ortho to para position, hypothesizing that electronic and steric effects might influence metabolic vulnerability.
Seventeen analogs were synthesized using a multi-step protocol involving cyclization, methylation, condensation with 3-ethylrhodanine, and final deprotection. Compounds were evaluated for metabolic stability using mouse liver microsomes at 37°C over 30 minutes. Notably, JG-23, featuring a 4-chloro substitution and para-pyridine configuration, showed the most significant improvement, retaining 52% of its original concentration after 30 minutes—12-fold greater than YM-08. This enhancement was consistent across multiple time points and confirmed by kinetic analysis, which yielded a half-life of 36 minutes for JG-23 compared to less than 3 minutes for YM-08.
Further validation confirmed that JG-23 effectively reduces total tau levels in both HeLaC3 and SH-SY5Y cell lines.57-83-0 manufacturer In HeLaC3 cells, treatment with JG-23 at concentrations above 10 µM led to a dose-dependent decrease in tau protein, as measured by Western blot.2996998-09-3 Biological Activity Similarly, in SH-SY5Y cells, which express endogenous tau, JG-23 reduced tau levels by approximately 80% without altering expression of stress markers such as Hsp72 or Hsp90.PMID:30422533 These results indicate that JG-23 selectively enhances tau degradation without triggering cellular stress responses.
This work demonstrates that rational chemical modification—specifically halogenation and strategic heteroatom positioning—can dramatically improve the metabolic stability of Hsp70-targeting compounds without compromising their functional activity. JG-23 represents a robust and stable chemical probe suitable for investigating tau homeostasis in complex biological systems. Its favorable pharmacokinetic profile paves the way for future in vivo studies aimed at evaluating the therapeutic potential of Hsp70 modulation in tauopathy models.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com